Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air ® real-world data.
Bernardo Sousa-PintoAna Sá-SousaRafael José VieiraRita AmaralLudger KlimekWienczyslawa CzarlewskiJosep M AntóOliver PfaarAnna BedbrookVioleta KvedarieneMaria Teresa VenturaIgnacio J AnsoteguiKarl-Christian BergmannLuisa BrussinoG Walter CanonicaVictoria CardonaPedro Carreiro-MartinsTomas CasaleLorenzo CecchiTomás ChivatoDerek K ChuCemal CingiElísio M CostaÁlvaro Augusto CruzGiulia De FeoPhilippe DevillierWytske J FokkensMina GagaBilun GemicioğluTari HaahtelaJuan Carlos IvancevichZhanat IspayevaMarek JutelPiotr KunaIgor KaidashevHelga KraxnerDésirée Erlinda Larenas-LinnemannDaniel LauneBrian LipworthRenaud LouisMichael MakrisRiccardo MontiMario Morais-AlmeidaRalph MösgesJoaquim MullolMikaëla OdemyrYoshitaka OkamotoNikolaos G PapadopoulosVincenzo PatellaNhân Pham-ThiFrederico S RegateiroSietze ReitsmaPhilip W RouadiBoleslaw SamolinskiMilan SovaAna Todo-BomLuis Taborda-BarataPeter-Valentin TomazicSanna Toppila-SalmiJoaquin SastreIoanna TsiligianniArunas ValiulisOlivier VandenplasDana WallaceSusan WasermanArzu YorganciogluMihaela ZidarnTorsten ZuberbierJoão A FonsecaJean BousquetPublished in: Allergy (2022)
Allergic rhinitis medication patterns are similar across European regions. One third of treatment days involved co-medication. These findings suggest that patients treat themselves according to their symptoms (irrespective of how they understand AR) and that co-medication use is driven by symptom severity.